Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Neurogastroenterol Motil. 2011 Aug;23(8):693-6. doi: 10.1111/j.1365-2982.2011.01752.x.

Evolving concepts in chronic constipation in Europe and elsewhere: not worlds apart.

Author information

  • 1Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA. fcremoni@bidmc.harvard.edu

Abstract

Chronic constipation (CC) is widely prevalent in the Western world, with a significant negative impact on quality of life, yet new and effective pharmacological and non-pharmacological treatment options have only recently emerged. The article by Tack and colleagues in the current issue of NGM is timely with the recent introduction of the serotonin type 4 receptor agonist prucalopride in Europe and wider acceptance of anorectal biofeedback for patients with pelvic floor dyssynergia. This Editorial (i) highlights the importance of identifying patients with pelvic floor dysfunction who are candidates for pelvic floor retraining programs and (ii) discusses the potential limitations of the 5-HT4 agonist, prucalopride, as an early option in the treatment algorithm for CC.

© 2011 Blackwell Publishing Ltd.

Comment on

PMID:
21762282
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Blackwell Publishing
    Loading ...
    Write to the Help Desk